Effect of CHRFAM7A Δ2bp gene variant on secondary inflammation after spinal cord injury.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
11
2020
accepted:
20
04
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
21
10
2021
Statut:
epublish
Résumé
The α7 neuronal nicotinic acetylcholine receptors (α7nAChRs) are essential for anti-inflammatory responses. The human-specific CHRFAM7A gene and its 2bp deletion polymorphism (Δ2bp variant) encodes a structurally-deficient α7nAChRs that may impact the anti-inflammatory function. We studied 45 spinal cord injury (SCI) patients for up to six weeks post SCI to investigate the role of the Δ2bp variant on multiple circulating inflammatory mediators and two outcome measures (neuropathic pain and risk of pressure ulcers). The patient's SCI were classified as either severe or mild. Missing values were imputed. Overall genetic effect was conducted with independent sample t-test and corrected with false discovery rate (FDR). Univariate analysis and regression analysis were applied to evaluate the Δ2bp effects on temporal variation of inflammatory mediators post SCI and their interaction with outcome measures. In severe SCI, the Δ2bp carriers showed higher levels of circulating inflammatory mediators than the Δ2bp non-carriers in TNF-α (FDR = 9.6x10-4), IFN-γ (FDR = 1.3x10-3), IL-13 (FDR = 1.6x10-3), CCL11 (FDR = 2.1x10-3), IL-12p70 (FDR = 2.2x10-3), IL-8 (FDR = 2.2x10-3), CXCL10 (FDR = 3.1x10-3), CCL4 (FDR = 5.7x10-3), IL-12p40 (FDR = 7.1x10-3), IL-1b (FDR = 0.014), IL-15 (FDR = 0.024), and IL-2 (FDR = 0.037). IL-8 and CCL2 were negatively associated with days post injury (DPI) for the Δ2bp carriers (P = 2x10-7 and P = 2x10-8, respectively) and IL-5 was positively associated with DPI for the Δ2bp non-carriers (P = 0.015). Neuropathic pain was marginally positively associated with IL-13 for the Δ2bp carriers (P = 0.056). In mild SCI, the Δ2bp carriers had lower circulating levels of IL-15 (FDR = 0.04) than the Δ2bp non-carriers. Temporal variation of inflammatory mediators post SCI was not associated with the Δ2bp variant. For the mild SCI Δ2bp carriers, risk of pressure ulcers was positively associated with circulating levels of IFN-γ, CXCL10, and CCL4 and negatively associated with circulating levels of IL-12p70. These findings support an important role for the human-specific CHRFAM7A Δ2bp gene variant in modifying anti-inflammatory function of α7nAChRs following SCI.
Identifiants
pubmed: 33956875
doi: 10.1371/journal.pone.0251110
pii: PONE-D-20-34479
pmc: PMC8101719
doi:
Substances chimiques
Chrna7 protein, human
0
alpha7 Nicotinic Acetylcholine Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0251110Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurosci Res. 2004 Sep 1;77(5):701-8
pubmed: 15352216
Physiol Rev. 2009 Jan;89(1):73-120
pubmed: 19126755
Br J Pharmacol. 2007 Aug;151(7):915-29
pubmed: 17502850
Nat Immunol. 2005 Aug;6(8):756-7
pubmed: 16034431
Ann Surg. 1994 Jul;220(1):10-8
pubmed: 8024353
Nurs Res. 1987 Jul-Aug;36(4):205-10
pubmed: 3299278
Top Spinal Cord Inj Rehabil. 2017 Summer;23(3):207-217
pubmed: 29339896
Biochem Pharmacol. 2011 Oct 15;82(8):904-14
pubmed: 21718690
Nature. 2003 Jan 23;421(6921):384-8
pubmed: 12508119
J Pharmacol Sci. 2017 Jan;133(1):53-56
pubmed: 28057412
J Intern Med. 2009 Jun;265(6):663-79
pubmed: 19493060
Arch Pharm Res. 2013 Sep;36(9):1039-50
pubmed: 23771498
J Am Geriatr Soc. 2012 Sep;60(9):1603-8
pubmed: 22985136
J Pain Symptom Manage. 2011 Jun;41(6):1073-93
pubmed: 21621130
J Leukoc Biol. 1994 Nov;56(5):559-64
pubmed: 7964163
Mol Med. 2015 Apr 03;21:323-36
pubmed: 25860877
Trends Neurosci. 2018 Feb;41(2):67-70
pubmed: 29405928
Science. 2011 Oct 7;334(6052):98-101
pubmed: 21921156
Inflamm Regen. 2016 Oct 17;36:20
pubmed: 29259693
J Exp Med. 2012 Jun 4;209(6):1057-68
pubmed: 22665702
Pain. 2013 Dec;154 Suppl 1:S71-S76
pubmed: 23375163
J Neurotrauma. 2019 Nov 1;36(21):3026-3033
pubmed: 30924722
J Neuroinflammation. 2014 Aug 28;11:150
pubmed: 25163400
Pain. 2011 Jan;152(1):14-27
pubmed: 20851519
J Biol Chem. 2011 Jan 7;286(1):594-606
pubmed: 21047781
Neural Plast. 2013;2013:945034
pubmed: 24288627
J Clin Invest. 2007 Feb;117(2):289-96
pubmed: 17273548
Spinal Cord. 2019 Oct;57(10):819-831
pubmed: 31273298
Brain Res. 2019 Jul 15;1715:57-65
pubmed: 30898676
Eur J Hum Genet. 2008 Nov;16(11):1364-71
pubmed: 18545269
PLoS One. 2013 Dec 03;8(12):e79804
pubmed: 24312451
Clin Orthop Relat Res. 2017 May;475(5):1499-1504
pubmed: 27815685
Am J Hum Biol. 2015 Jul-Aug;27(4):570-5
pubmed: 25757675
Curr Neuropharmacol. 2018;16(4):415-425
pubmed: 28820052
Am J Med Genet B Neuropsychiatr Genet. 2006 Sep 5;141B(6):571-5
pubmed: 16823804
J Neurosci Res. 1996 Dec 15;46(6):727-33
pubmed: 8978507
Brain Res. 2009 Sep 29;1291:1-11
pubmed: 19631623
Lancet. 1997 Feb 15;349(9050):490-5
pubmed: 9040590
J Neurotrauma. 2010 Apr;27(4):669-82
pubmed: 20038240
Genomics. 1998 Sep 1;52(2):173-85
pubmed: 9782083
Exp Neurol. 2003 Nov;184(1):456-63
pubmed: 14637115
Mol Med. 2012 May 09;18:539-43
pubmed: 22183893
Curr Opin Genet Dev. 2016 Dec;41:44-52
pubmed: 27584858
Curr Opin Neurol. 2002 Jun;15(3):355-60
pubmed: 12045737
Neuropharmacology. 2015 Sep;96(Pt B):274-88
pubmed: 25701707
J Neurosci Res. 2006 Sep;84(4):724-34
pubmed: 16862543
Trends Mol Med. 2004 Dec;10(12):580-3
pubmed: 15567326
FEBS Lett. 2018 Apr;592(7):1045-1062
pubmed: 29030971
FEBS Open Bio. 2017 Aug 07;7(9):1350-1361
pubmed: 28904864
J Leukoc Biol. 1999 Jun;65(6):744-9
pubmed: 10380894
Nat Rev Immunol. 2009 Jun;9(6):418-28
pubmed: 19461672
Cytogenet Genome Res. 2005;108(1-3):73-82
pubmed: 15545718
Int J Mol Sci. 2016 Dec 11;17(12):
pubmed: 27973441
J Immunol. 2002 Apr 1;168(7):3195-204
pubmed: 11907072
Adv Exp Med Biol. 2016;941:117-138
pubmed: 27734411